Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.
Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar
Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.